# Chendu DIAO Pharmaceutical Group CO., LTD.: Phase 1 study in Obesity, Overweight, T2DM (Type 2 Diabetes Mellitus) (32 participants)

**Score:** 50/100

| Field | Value |
|---|---|
| Sponsor | Chendu DIAO Pharmaceutical Group CO., LTD. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic Function |
| NCT ID | NCT07877038 |
| Phase | Phase 1 |
| Status | not yet recruiting |
| Conditions | Obesity, Overweight; T2DM (Type 2 Diabetes Mellitus) |
| Intervention types | drug |
| Target enrollment | 32 |
| Posted | 2026-10-15 |
| Planned start | 2026-10-22 |
| Event | Newly registered study |
| Event date | 2026-10-15 |

## Why this score
- Industry sponsor (buys outsourced services).
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07877038). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.